

	<b>O-FIS Qualitätsmanagementsystem</b> Formblatt <b>Collection and Cohort Profile</b>	CL312 Seite 1 von 1
---	---	------------------------

## 1. General Information

<b>Biobank project number</b>	5009_16
<b>Title (Study Name)</b>	Impact of EMPagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction (EMMY-Trial) - a phase III Study
<b>Principal investigator</b>	Assoc.-Prof. Dr. Harald Sourij and Assoc.-Prof. Dr. Dirk von Lewinski
<b>Contact information</b>	<a href="mailto:pm-biobank@medunigraz.at">pm-biobank@medunigraz.at</a>
<b>Funding agency</b>	

## 2. Description

<p>This is a national, randomized, prospective, placebo-controlled, double blind, multicenter study in patients with acute myocardial infarction. The aim of this mechanistic study is to investigate the impact of Empagliflozin on cardiac function and biomarkers for heart failure in patients with acute myocardial infarction. Since previous trials in acute myocardial infarction using aldosterone blockers demonstrated that an early intervention might be crucial for a beneficial outcome, the study team has chosen to start treatment within 72 hours after performance of a coronary angiography for acute myocardial infarction. In this RCT Empagliflozin/Placebo (10mg once daily orally) will be administered.</p>
--

## 3. Details

<b>ICD 10/O codes / Healthy</b>	I21		
<b>Key words</b>	myocardial infarction, empagliflozin, RCT, placebo, SGLT-2 inhibitor, heart failure		
<b>Collection / Cohort size (subjects / visits)</b>	476 patients - 3 study visits		
<b>Informed Consent (IC)</b>	<input type="checkbox"/> Broad Biobank IC		
	<input checked="" type="checkbox"/> Specific Study IC		
<b>Status</b>	<input checked="" type="checkbox"/> In progress / compl. date: 12/2020		
	<input type="checkbox"/> Completed		
<b>Inclusion criteria</b>	<b>Age distribution</b>	18-80 years	
	<b>Sex distribution (f:m)</b>	~ 50:50	
	<b>Others</b>	⇒ Details see article	
<b>Access type</b>	<input type="checkbox"/> Cooperation only	<input checked="" type="checkbox"/> Cooperation preferred	
<b>Earliest access</b>	06/2019		
<b>Quality-standards</b>	<input type="checkbox"/> CEN/TS	<input checked="" type="checkbox"/> ISO 9001:2015 (SOPs)	
<b>Associated publications / references</b>			

## 4. Material available (aliquot size) and storage conditions

<b>Material</b>	<input checked="" type="checkbox"/> Serum (µl)		<input checked="" type="checkbox"/> -80°C	<input type="checkbox"/> liq. N <sub>2</sub>
	<input checked="" type="checkbox"/> Plasma (µl)		<input checked="" type="checkbox"/> -80°C	<input type="checkbox"/> liq. N <sub>2</sub>
	<input checked="" type="checkbox"/> Whole blood (µl)		<input checked="" type="checkbox"/> -80°C	
	<input checked="" type="checkbox"/> Na-Citrat (µl)		<input checked="" type="checkbox"/> -80°C	
	<input checked="" type="checkbox"/> Urine (µl)		<input checked="" type="checkbox"/> -80°C	